BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Rhea-AI Summary

RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Genetic Technologies on Bloomberg TV this Saturday, October 12, at 7 p.m. ET. The interviews will feature:

1. Cuong Do, President and CEO of BioVie, discussing the company's late-stage clinical programs for neurodegeneration and liver disease. Key points include:

• Bezisterim's ability to modulate TNFα production, leading to clinical improvements
• Planned Phase 2b trial for Parkinson's in late 2024
• Upcoming Phase 3 trial for Alzheimer's in late 2025
• Ongoing partnering discussions for bezisterim's geographic rights
• Plans for an ascites Phase 3 trial

2. Peter Rubinstein, Executive Chairman of Genetic Technologies, providing a corporate update on:

• EasyDNA platform with $7 million in annual recurring revenues
• Expanding product portfolio with over 50 risk assessment tests
• B2B commercialization strategy for geneType multi-risk test
• Focus on direct-to-consumer testing programs
• Recent corporate restructure to reduce cash burn

Positive

• BioVie's bezisterim has shown clinical improvements in Parkinson's and Alzheimer's disease
• BioVie plans to launch a Phase 2b trial for Parkinson's in late 2024
• BioVie aims to initiate a Phase 3 trial for Alzheimer's in late 2025
• BioVie is in ongoing partnering discussions for bezisterim's geographic rights
• Genetic Technologies' EasyDNA platform generates $7 million in annual recurring revenues
• Genetic Technologies has over 50 risk assessment tests in 14 categories
• Genetic Technologies has implemented a corporate restructure to reduce cash burn

Negative

• None.

ORLANDO, FL / ACCESSWIRE / October 11, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Genetic Technologies Limited (Nasdaq:GENE)(ASX:GTG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

Access the interviews in their entirety at:

• BioVie: https://www.redchip.com/assets/access/bivi_access

• Genetic Technologies: https://www.redchip.com/assets/access/gene_access

In an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical programs targeting unmet medical needs in neurodegeneration and liver disease. BioVie's lead asset, bezisterim (formerly NE3107), has demonstrated the ability to modulate TNFα production, leading to significant clinical improvements. Patients treated with bezisterim experienced reduced inflammation and insulin resistance, improved motor control and "morning on" symptoms in Parkinson's disease (PD), enhanced cognition and function, and better brain imaging scans in Alzheimer's disease (AD), as well as reduced DNA methylation levels. The Company's strategic priorities include launching a Phase 2b trial for Parkinson's in late 2024, initiating a Phase 3 trial for Alzheimer's in late 2025 with a new once-daily formulation of bezisterim, continuing partnering discussions for bezisterim's geographic rights, and commencing an ascites Phase 3 trial upon identifying a suitable partner.

Peter Rubinstein, Executive Chairman of Genetic Technologies, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Genetic Technologies' EasyDNA platform has over $7 million in annual recurring revenues in the Paternity and Health and wellness space across global markets along with its expanding product portfolio including more than 50 risk assessment tests in 14 test categories covered by 25 patents granted and nine patents pending. In addition to its B2B commercialization strategy for its flagship geneType multi-risk test, Genetic Technologies is also focused on expanding its direct-to-consumer testing programs. The global market for predictive genomics is expected to reach $4.6 billion by 2025, growing at a CAGR of 17%+. A recent corporate restructure has dramatically reduced cash burn to allow the company to focus on sales and commercialization of its world leading technology.

About BioVie Inc.

BioVie Inc. (NASDAQ:BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of ERK and NFκB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of AD and PD. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with U.S. Food and Drug Administration ("FDA") Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit www.bioviepharma.com.

About Genetic Technologies

Genetic Technologies Limited (ASX:GTG)(Nasdaq:GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness, and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com.

About RedChip Companies

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

To learn more about RedChip's products and services, please visit:

https://www.redchip.com/corporate/investor_relations

"Discovering Tomorrow's Blue Chips Today"™

Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

Follow RedChip on Twitter: https://twitter.com/RedChip

Follow RedChip on YouTube: https://www.youtube.com/@redchip

Follow RedChip on Rumble: https://rumble.com/c/c-3068340

Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

Contact:

Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com

--END--

SOURCE: RedChip

View the original press release on accesswire.com

FAQ

When will BioVie (BIVI) launch its Phase 2b trial for Parkinson's disease?

BioVie (BIVI) plans to launch its Phase 2b trial for Parkinson's disease in late 2024.

What is the timeline for BioVie's (BIVI) Phase 3 trial for Alzheimer's disease?

BioVie (BIVI) aims to initiate a Phase 3 trial for Alzheimer's disease in late 2025 with a new once-daily formulation of bezisterim.

What are the key clinical improvements shown by BioVie's (BIVI) bezisterim?

BioVie's (BIVI) bezisterim has demonstrated reduced inflammation, improved motor control in Parkinson's disease, enhanced cognition in Alzheimer's disease, and reduced DNA methylation levels.

What is the annual recurring revenue of Genetic Technologies' EasyDNA platform?

Genetic Technologies' EasyDNA platform generates over $7 million in annual recurring revenues in the Paternity and Health and wellness space across global markets.